|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The NPS system controls several biological functions, including anxiety, wakefulness, locomotor activity, food intake, and pain transmission.
|
31326375 |
2019 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
These data suggest that rAAV-NPS application deserves further attention as a potential treatment strategy for anxiety in humans.
|
30914309 |
2019 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Therefore, NPS might represent a treatment option for neuropsychiatric disorders, such as anxiety disorders, even more so as single nucleotide polymorphisms in the human NPS receptor gene have been associated with increased anxiety traits that contribute to the pathogenesis of fear- and anxiety-related disorders.
|
30112573 |
2019 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
In previous studies, neuropeptide S (NPS) and its cognate receptor (NPSR) have been involved in the pathogenesis of anxiety disorders in previous studies.
|
30190127 |
2018 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Given the behavioral actions of this peptide and the wide innervation pattern, we examined the cellular effects of NPS within two brain stem nuclei known to play a critical role in anxiety and arousal: the dorsal raphe (DR) and laterodorsal tegmentum (LDT).
|
28655610 |
2017 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
In conclusion, our results indicate a significant role of the OXT system in mediating the effects of NPS on anxiety, and fill an important gap in our understanding of brain neuropeptide interactions in the context of regulation of emotional behavior within the hypothalamus.<b>SIGNIFICANCE STATEMENT</b> Given the rising scientific interest in neuropeptide research in the context of emotional and stress-related behaviors, our findings demonstrate a novel intrahypothalamic mechanism involving paraventricular oxytocin neurons that express the neuropeptide S receptor.
|
29118105 |
2017 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The neuropeptide S (NPS) system contributes to the pathogenesis of anxiety.
|
26503268 |
2017 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Overall, phenotypical changes in NPS<sup>-/-</sup> mice are similar to those observed in NPS receptor knockout mice and support earlier findings that suggest major functions of the NPS system in arousal, regulation of anxiety and stress, and memory formation.
|
28548278 |
2017 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Neuropeptide S (NPS), an endogenous neuropeptide that improves short term memory, activates arousal and decreases anxiety is likely to counteract the SR-induced impairment of STM.
|
28941995 |
2017 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The neuropeptide S (NPS) and its receptor NPSR have captured attention in the pathogenesis of anxiety disorders.
|
25971599 |
2015 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Our results underline the notion of a genetically driven rapid and dynamic response mechanism in the neural regulation of human anxiety and further strengthen the emerging role of the NPS system in anxiety.
|
26235955 |
2015 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
NPSR1 encodes the receptor for neuropeptide S (NPS) and NPS-NPSR1 signaling is involved in anxiety, inflammation, and nociception.
|
25091462 |
2014 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Neuropeptide S and its receptor NPSR1 are involved in the regulation of arousal, attention and anxiety.
|
23325374 |
2014 |
|
Anxiety Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Since central administration of neuropeptide S (NPS) has been shown to exert anxiolytic effects on rodent behavior in a number of studies, genetic variants of its cognate G-protein coupled receptor (NPSR1) became the focus of several recent human studies on anxiety and anxiety disorders.
|
23103692 |
2013 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The neuropeptide S (NPS) and its receptor NPSR represent a transmitter system critically involved in the modulation of anxiety and arousal in rodents.
|
23466585 |
2013 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
These findings further corroborate a major role of the neuropeptide S system in the pathogenesis of anxiety and suggest a potentially beneficial use of therapeutic agents targeting the NPS system in anxiety disorders.
|
23319044 |
2013 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
These results not only enlighten the path of NPS in the brain, but also establish a non-invasive method for NPS administration in mice, thus strongly encouraging translation into a novel therapeutic approach for pathological anxiety in humans.
|
22278093 |
2012 |
|
Anxiety Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
CCK interacts with several anxiety-relevant neurotransmitters such as the serotonergic, GABA-ergic and noradrenergic system as well as with endocannabinoids, NPY and NPS.
|
22553078 |
2012 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
In summary, the present findings - extending previous evidence from rodent studies - for the first time provide support for a complex, non-linear interaction of the neuropeptide S and adenosinergic systems affecting the affect-modulated startle response as an intermediate phenotype of anxiety in humans.
|
22399050 |
2012 |
|
Anxiety Disorders
|
0.400 |
Therapeutic
|
group |
CTD_human |
Synthesis and separation of the enantiomers of the neuropeptide S receptor antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68).
|
21466221 |
2011 |
|
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In animal models, NPS and its receptor (NPSR) were shown to be highly expressed in the amygdala, a central structure in the fear circuit, also known to be hyper-responsive in anxiety disorders.
|
21525857 |
2011 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
Synthesis and separation of the enantiomers of the neuropeptide S receptor antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68).
|
21466221 |
2011 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
In this study, a multilevel approach was applied to further elucidate the role of NPS in the etiology of human anxiety.
|
20603625 |
2011 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
We addressed here the role of NPS and NPSR1 as susceptibility genes for human anxiety disorders.
|
20705147 |
2010 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
Our results suggest that NPS receptors may be an important target for drug abuse research and treatment and that CRF(1) mediates the cocaine-seeking and locomotor stimulant effects of NPS, but not its effects on anxiety-like behavior.
|
19339610 |
2009 |